Omalizumab improves asthma-related quality of life in patients with severe allergic asthma  Albert Finn, MDa, Gary Gross, MDb, Julius van Bavel, MDc,

Slides:



Advertisements
Similar presentations
Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane- beclomethasone extrafine inhalation aerosol), in asthma Jennifer.
Advertisements

W.Travis Cain, MDa, Greg Cable, PhDb, John J. Oppenheimer, MDc 
House dust mite avoidance measures improve peak flow and symptoms in patients with allergy but without asthma: A possible delay in the manifestation of.
Double-blind placebo-controlled study of the efficacy of oral terfenadine in the treatment of chronic fatigue syndrome  Paul Steinberg, MDa, Bruce E.
Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy  Monica B. Arvidsson, MD, Olle.
Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M
F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc 
Ulrich Wahn, MDa. ‡, Eli O. Meltzer, MDb. ‡, Albert F. Finn, MDc
Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction  Robert A. Nathan, MDa, Jonathan A.
A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children  Mark Boguniewicz, MDa, Virginia C. Fiedler,
Asthma and increased bronchial responsiveness in elite athletes: Atopy and sport event as risk factors  Ilkka J. Helenius, MDa, Heikki O. Tikkanen, MDb,
The effect of omalizumab on nasal allergic inflammation
Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis  Paul H. Ratner,
Badrul A. Chowdhury, MD, PhD 
Hydroxychloroquine improves airflow and lowers circulating IgE levels in subjects with moderate symptomatic asthma  B.Lauren Charous, MD, Elkan F. Halpern,
Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis  James.
As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis  Albert Jen, MD, Fuad Baroody, MD, Marcy de Tineo,
Harold B. Kaiser, MDa, Steven R. Findlay, MD†, John W
Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis  George Philip, MD, Janet van Adelsberg, MD, Thomas Loeys, PhD, Nancy.
Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: A randomized clinical trial  William Busse, MDa,
Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with.
Low-dose levalbuterol in children with asthma: Safety and efficacy in comparison with placebo and racemic albuterol  Henry Milgrom, MDa, David P. Skoner,
Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid–dependent, persistent asthma  Gail.
A dose-ranging study of the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis with an acute model  John M.
A review of the current guidelines for allergic rhinitis and asthma
Early decreases in blood eosinophil levels with reslizumab
Physician-targeted program on inhaled therapy for childhood asthma
News & Notes Journal of Allergy and Clinical Immunology
James P. Kemp, MDa, David A. Cook, MDb, Gary A
Selective allergic reactions to clavulanic acid
Inflammatory cells, cytokine and chemokine expression in asthma immunocytochemistry and in situ hybridization  Qutayba Hamid, MD, PhD, Editor  Journal.
Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: A randomized, double-blind, placebo-controlled.
Efficacy of nebulized budesonide in treatment of severe infantile asthma: A double-blind study  Jacques de Blic, MDa, Christophe Delacourt, MDa, Muriel.
Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma  William.
Subjective and objective assessments in patients with seasonal allergic rhinitis: Effects of therapy with mometasone furoate nasal spray  Eli O. Meltzer,
Exercise-induced bronchoconstriction in children: Montelukast attenuates the immediate-phase and late-phase responses  Raul E. Melo, MD, Dirceu Solé,
Jack M. Becker, MDa, Anjali Arora, MDb, Richard J
F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc 
Model for outcomes assessment of antihistamine use for seasonal allergic rhinitis  Robert P. Harvey, MD, Carolyn Comer, MD, Barbara Sanders, MD, Ross Westley,
Vascular endothelial growth factor in patients with acute asthma
Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients.
Thomas B. Casale, MDa, I. Leonard Bernstein, MDb, William W
A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma  Gordon D. Raphael, MDa, Robert.
News & Notes Journal of Allergy and Clinical Immunology
The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis  Anjuli S. Nayak, MDa, Mark H.
Fluticasone propionate powder: Oral corticosteroid–sparing effect and improved lung function and quality of life in patients with severe chronic asthma 
Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment
A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray 
Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma  Eugene R. Bleecker, MDa, Michael J. Welch, MDb,
A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein.
The 30th anniversary of the American Board of Allergy and Immunology: Then and now  Lynn Des Prez a, Charles E. Reed, MD, Lawrence B. Schwartz, MDb, John.
Steroid-sparing effects of fluticasone propionate 100 μg and salmeterol 50 μg administered twice daily in a single product in patients previously controlled.
The Editors' Choice Journal of Allergy and Clinical Immunology
Comparison of effects of topical levocabastine and nedocromil sodium on the early response in a conjunctival provocation test with allergen  Catherine.
Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma  James P.
Studies on the relationship between the level of specific IgE antibodies and the clinical expression of allergy: I. Definition of levels distinguishing.
Abnormalities of cell and mediator levels in bronchoalveolar lavage fluid of patients with mild asthma  Sally E. Wenzel, MD  Journal of Allergy and Clinical.
Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M
Magnitude of effect of asthma treatments on Asthma Quality of Life Questionnaire and Asthma Control Questionnaire scores: Systematic review and network.
National trends in asthma visits and asthma pharmacotherapy,
Larry C. Borish, MDa, Harold S
Andrea J. Apter, MD, MSca, c, Susan T
The environmental predictors of allergic disease
Airway remodeling-associated mediators in moderate to severe asthma: Effect of steroids on TGF-β, IL-11, IL-17, and type I and type III collagen expression 
Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal.
Asthma symptoms and airway hyperresponsiveness are lower during treatment with nedocromil sodium than during treatment with regular inhaled albuterol 
Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial  Eli O. Meltzer, MDa,
News & Notes Journal of Allergy and Clinical Immunology
Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma  Philippe Gevaert, MD, PhD, Lien Calus, MD, Thibaut Van Zele,
Desloratadine: A new, nonsedating, oral antihistamine
Presentation transcript:

Omalizumab improves asthma-related quality of life in patients with severe allergic asthma  Albert Finn, MDa, Gary Gross, MDb, Julius van Bavel, MDc, Theodore Lee, MDd, Hugh Windom, MDe, François Everhard, MSf, Angel Fowler-Taylor, RPhg, Jeen Liu, PhDg, Niroo Gupta, MD, PhDg  Journal of Allergy and Clinical Immunology  Volume 111, Issue 2, Pages 278-284 (February 2003) DOI: 10.1067/mai.2003.54 Copyright © 2003 Mosby, Inc. Terms and Conditions

Fig. 1 Least-square mean change from baseline in asthma-related QOL scores, as determined by using the Juniper AQLQ,17 during treatment with omalizumab or placebo in patients with severe allergic asthma. An increase in score of 0.5 points or greater from baseline indicates a clinically significant improvement.18 *P < .05, **P <.01, and ***P < .001 versus placebo. Journal of Allergy and Clinical Immunology 2003 111, 278-284DOI: (10.1067/mai.2003.54) Copyright © 2003 Mosby, Inc. Terms and Conditions

Fig. 2 Proportion of patients achieving a clinically meaningful improvement in asthma-related QOL (defined as an increase in score of ≥0.5 points from baseline18) on completion of each phase of the study. *P < .05, **P < .01, and ***P < .001 versus placebo. Journal of Allergy and Clinical Immunology 2003 111, 278-284DOI: (10.1067/mai.2003.54) Copyright © 2003 Mosby, Inc. Terms and Conditions

Fig. 3 Proportion of patients achieving a large improvement in QOL scores (defined as an increase in score of ≥1.5 points from baseline18) during treatment with omalizumab or placebo in patients with severe allergic asthma. *P < .05, **P < .01, and ***P < .001 versus placebo. Journal of Allergy and Clinical Immunology 2003 111, 278-284DOI: (10.1067/mai.2003.54) Copyright © 2003 Mosby, Inc. Terms and Conditions

Fig. 4 Patient and investigator global evaluations of treatment effectiveness after 28 weeks' treatment with omalizumab or placebo in patients with severe allergic asthma. Journal of Allergy and Clinical Immunology 2003 111, 278-284DOI: (10.1067/mai.2003.54) Copyright © 2003 Mosby, Inc. Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.